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Stereotactic ablative body radiotherapy (SABR) is a newer method of ultra hypo fractionated
radiotherapy that uses combination of image-guided radiotherapy (IGRT) and intensity-
modulated radiotherapy (IMRT) or volumetric modulated arc therapy (VMAT), to deliver high
doses of radiation in a few fractions to a target, at the same time sparing the surrounding
organs at risk (OAR). SABR is ideal for treating small volumes of disease and has been intro-
duced in a number of disease sites including brain, lung, liver, spine, and prostate. Given the
radiobiological advantages of treating prostate cancer with high doses per fraction, SABR is
becoming a standard of care for low and intermediate-risk prostate cancer patients based
upon the results from Sunnybrook and also the US-based prostate SABR consortium.This
review examines the development of moderate and ultra hypo-fractionation schedules at
the Odette Cancer centre, Sunnybrook Health Sciences. Moderate hypo-fractionation pro-
tocol was first developed in 2001 for intermediate-risk prostate cancer and from there on
different treatment schedules including SABR evolved for all risk groups.
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INTRODUCTION
Prostate cancer is the most prevalent male cancer in the western
world with varying management options as per the individual’s
risk stratification, functional domain, and preference.
There is now convincing evidence that radiotherapy dose esca-
lation is beneficial across all risk groups of prostate cancer patients
(1, 2). Dose escalation beyond 81 Gy with conventional radio-
therapy techniques has posed problems due to the increase in
bowel toxicity (2) despite the use of image guided (IGRT) and
intensity-modulated radiotherapy (IMRT).
Alternative means of safe radiotherapy dose escalation are
low dose rate (LDR) or high-dose rate (HDR) brachytherapy
alone or in combination with EBRT. While LDR brachytherapy
monotherapy is established for low risk and selective intermediate-
risk patients, HDR monotherapy remains experimental (3). HDR
boost in combination with EBRT is an excellent example of
safe radiotherapy dose escalation (4). Despite this being an
appealing option, limitations include patient fitness for anes-
thetic exposure, urinary morbidity, and limited operating room
capacity.
One notion that has revolutionized the field of radiotherapy has
been the purported low α/β ratio for prostate cancer (5). Miralbell
et al. presented the outcomes of 5969 patients, which calculated
the α/β to be 1.3, 1.6, and 1.8 for low, intermediate, and high-risk
prostate cancers (6). This in association with a higher α/β ratio for
acute (10) and late (≈3–4) responding tissues, can theoretically
improve the therapeutic ratio of hypofractionated radiotherapy
(7). Strategies include either moderate hypo-fractionation (2–
3.5 Gy per fraction) or ultra hypo-fractionation (>3.5 Gy per
fraction).
These concepts have led to the development of various prostate
hypofractionated accelerated radio therapy (pHART) protocols at
the Odette Cancer Centre, Sunnybrook Health Sciences.
This is the first report describing the evolution of various
gantry-based coplanar radiotherapy techniques for hypofraction-
ation, adapted in accordance with the emerging radiotherapy tech-
nology. This review also discusses the role of hypo-fractionation
in various prostate cancer risk groups and is the first to include a
significant number of high-risk patients.
MODERATE HYPOFRACTIONATION
pHART1 – INTERMEDIATE RISK
In 2001, pHART1 was developed to treat 33 intermediate-risk
prostate cancer patients. The first phase involved delivering 42 Gy
in 21 fractions using three-dimensional conformal radiotherapy
(3DCRT) to the prostate and proximal seminal vesicles with a
10-mm planning target volume (PTV) margin. Following CT sim-
ulation, patients had digital fluoroscopic imaging of the gold seed
fiducials to quantify the respiratory induced prostatic motion. For
the first nine fractions, location of the implanted fiducials was
captured pre- and post-treatment using electronic portal imaging
device (EPID). Based on this data, a patient specific PTV margin
was derived and applied to the second phase of treatment, which
was an IMRT boost using a dose of 30 Gy in 10 daily fractions with
daily online EPID imaging.
The calculated mean PTV margin was 3 mm (range 2–
5 mm) in the lateral direction, 3 mm (range 2–7 mm) in the
superior–inferior, and 4 mm (range 2–8 mm) in the anterior–
posterior directions. Three patients (9.1%) developed acute grade
3 urgency/frequency. This study showed that the intra-fraction
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prostate movement was generally small, allowing for signifi-
cant PTV margin reduction if daily online imaging is per-
formed (8).
pHART2 – HIGH RISK
In 2004, 67 high-risk prostate cancer patients were enrolled into
a prospective, phase 1 study (pHART2) delivering 67.5 Gy to the
prostate in 25 fractions (2.7 Gy per day), while the pelvic nodes
received 45 Gy in 25 fractions over the same period, in conjunc-
tion with 3 years of ADT. Patients were treated using a simple four
field box technique (4FB) to deliver the pelvic elective nodal irra-
diation (ENI), while an optimized IMRT plan was used to deliver
the concomitant IMRT boost to the prostate. The acute toxicity
from this study has been very favorable (9).
In the next phase, the same dose-fractionation scheme was
employed for the same high-risk group in another 30 additional
patients. However, the radiotherapy technique was changed to
deliver both ENI and concomitant prostate boost using a single
optimized IMRT plan. The toxicity data has been updated for
these 97 patients in this phase I–II study with a median follow
up of 39 months. The incidence of acute grade 2 gastrointestinal
(GI) toxicity was 37% (no grade 3+); acute genitourinary (GU)
toxicity was 39% grade 2 and 4% grade 3. The late GI toxicity
was 7% grade 2 (no grade 3+) and late GU toxicity was 5% grade
2, 3% grade 3, and 1% grade 4. All severe toxicities (grade 3 or
greater) had resolved at the last follow-up visit. The 4-year bio-
chemical relapse-free survival (bRFS) rate was 90.5%. A quality
of life (QOL) study in this cohort demonstrated a modest decline
in urinary and bowel domain but this only led to mild distress in
QOL (10, 11).
Between 2007 and 2010, a third phase of the study was com-
pleted to treat an additional 144 patients (total 241 patients) with
the same dose-fractionation scheme. The acute toxicity results
from this entire cohort demonstrated a reduction in acute grade
2 GI toxicity, from 30.9% in patients receiving ENI with a 4FB
technique, to 7.2% in patients treated with IMRT and full bladder
filling protocol (12).
A phase 2 RCT study was opened in 2011 testing hypofraction-
ated schedule against conventional fractionation. Both schedules
provided ENI (46 Gy in 23 fractions in the conventional arm, and
48 Gy in 25 fractions in the hypofractionated boost arm) along
with 2–3 years of ADT. The conventional arm boosted the prostate
using cone-beam IGRT to a total prostate dose of 78 Gy (in 39
fractions) while the hypofractionated arm used gold seed fiducial
IGRT and simultaneously boosted the prostate to a dose of 68 Gy
in 25 fractions. The study is currently open and has accrued 64
patients to date (accrual goal 178).
In a recent systematic review of different hypo-fractionation
schedules, the bRFS was 73% (range, 3.3–95.4%) at a median
follow up of 36.5 months in the hypofractionated radiotherapy
cohort with less acute and late toxicities, compared with a median
bRFS of 66% (range, 34–79%) for the standard radiotherapy group
(13). In the Italian hypofractionated RCT, 168 patients with inter-
mediate and high-risk disease received a total of 9 months of
ADT and were randomized to 62 Gy in 20 fractions in 4 weeks or
80 Gy in 40 fractions over 8 weeks (14). At a median of 70 months
follow-up, bRFS was not statistically significant between the two
treatment cohorts (85 vs. 79%, p= 0.065). In the subgroup analy-
sis, patients with PSA≥20 ng/ml or Gleason 4+ 3 had better bRFS
with the hypo-fractionation schedule (15).
pHART4: POST-OPERATIVE RT
A hypo-fractionation schedule was developed for patients requir-
ing post-operative radiotherapy in 2009. Thirty patients with
pT3 NX-0 M0, positive surgical margins and/or a rising PSA
post-radical prostatectomy (two consecutive rises in PSA, at least
4 weeks apart) were included in the pHART4 study. Adjuvant ADT
was allowed at the discretion of the treating oncologist for up to
2 years.
Three gold seeds were inserted transperineally into the prostate
bed using local anesthesia (one at urogenital diaphragm, one at
each side of bladder neck). CTV was defined as per the widely
accepted RTOG consensus guidelines (16). PTV was derived by
adding a 4-mm symmetrical margin around the CTV (8). A dose
of 51 Gy in 17 daily fractions was prescribed with the 95% isodose
covering at least 99% of the PTV. Patients were treated using step-
and-shoot IMRT (SS-IMRT) technique. This schedule was chosen
to provide a biologically effective dose (BED) of 153 Gy, compara-
ble to 154 Gy as delivered by 66 Gy in 2 Gy fractions (assuming an
α/β of 1.5 Gy for prostate cancer).
At a median follow up of 24 months, only one patient had
acute grade 3 GU toxicity (3%), with gross hematuria and clots.
One patient developed greater than grade 1 (3%) late GU toxicity
and 2 (6%) patients with>grade 1 late GI toxicity. Three patients
(10%) had experienced biochemical failure, with two developing
metastatic disease (17).
Recent data from two other groups suggest that hypo-
fractionation is safe in the post-operative setting (18, 19).
ULTRA HYPOFRACTIONATION
pHART3: LOW RISK
A prospective, phase I/II ultra hypofractionated study (pHART3)
using a schedule of 35 Gy in five (weekly) fractions was started
in 2006 for low-risk prostate cancer patients. It was based on the
hypothesis that the weekly treatment would allow maximal nor-
mal tissue repair without compromising tumor control, facts later
confirmed by other groups (20).
The planning technique and 5-year results were described in
detail in our previous reports (21, 22). Prostate was contoured as
CTV and a 4-mm margin was added for PTV (8). Eighty four
patients were treated using a SS-IMRT technique and daily image
guidance using gold seed fiducials.
At a median follow up of 55 months (range 13–68 months),
the 5-year bRFS was 98% (95% confidence interval of 96–100%)
as per the Phoenix criteria (and 97% using ASTRO failure def-
inition) (22). Acute GI toxicity was 0, 10, and 67% for grades
3, 2, and 1, while 1, 19, and 71% developed new grade 3, 2,
and 1 GU toxicities (CTC v3.0 criteria), respectively. Four (5%)
patients developed grade 2 GU late toxicity (RTOG criteria). Two
required transurethral resection of the prostate and two required
alpha antagonists. Three patients (7%) had hematochezia requir-
ing treatment. One patient with a history of diverticulitis devel-
oped a rectocutaneous fistula post-radiation and refused definitive
surgical correction (grade 4 toxicity).
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These results are comparable to the outcomes from the stereo-
tactic ablative body radiotherapy (SABR) multi-institutional con-
sortium analysis. A median SABR dose of 36.25 Gy was delivered
using robotic non-coplanar technique in 4–5 fractions either daily
or on alternate days. At a median follow up of 36 months, the 5-
year bRFS was 95% for low-risk patients. In the 104 (77% of 135
pts) low-risk patients with a minimum follow up of 5 years, bRFS
was 99%. In the largest prostate cancer SABR series by Katz et al.,
acute (RTOG) and late (RTOG)≥grade 2 GU/GI toxicities (acute
Grade 2 GU-4%, GI-4%; Late Grade 2 GU-4%, and GI-2%) were
more favorable in the 50 patients who had 35 Gy in five daily frac-
tions when compared to phart 3 study. Late Grade 3+ GI toxicity
was 1% in phart 3 and this was not observed in the Katz et al. study.
It is difficult to conclude that there are clinically meaningful differ-
ences in toxicities between both techniques due to heterogeneity
in patient factors and toxicity scoring criteria (23).
pHART5: INTERMEDIATE RISK
pHART5 protocol for intermediate-risk prostate cancer was devel-
oped in 2010, which hypothesized that HDR brachytherapy doses
of 10–15 Gy can be delivered as a boost to the prostate with
acceptable toxicity rates using SABR. The phase one component
used MRI for prostate contouring, an intra rectal balloon, cone-
beam CT (CBCT) image guidance, and volumetric modulated arc
therapy (VMAT) for radiation delivery.
Phase 2 component began 2 weeks after the SABR boost. EPID
images were taken before treatment is initiated using IMRT to
deliver 2.5 Gy per day for 15 days delivering a total dose of
37.5 Gy. This unique dose-fractionation scheme is similar to the
prospective benchmark HDR brachytherapy study conducted at
Sunnybrook (24).
Ten patients in each cohort were each treated with an SABR
boost of 10, 12.5, and 15 Gy. Patients tolerated the SABR boost
very well with no acute grade 3 or higher toxicities seen. Patients
had less acute GU toxicity from the SABR boost (even at the 15-Gy
dose level) compared to the HDR boost (25). Ongoing follow-up
will yield late toxicities.
Katz et al. reported favorable toxicity outcomes in 41 interme-
diate and 32 high-risk patients who received 45 Gy EBRT with a
SABR boost (range 18–21 Gy in three fractions) (26). In a study
by Collins et al., 24 patients were treated with SABR to a dose of
19.5 Gy in three fractions followed by IMRT to a dose of 50.4 Gy
in 28 fractions. At a median follow up of 9.3 months, there was
no acute toxicity ≥Grade 3 (27). There is emerging data that
SABR plans can be optimized to reproduce the heterogeneity of
HDR (28).
pHART6: LOW AND INTERMEDIATE RISK
Oliai et al. demonstrated a dose response for intermediate and
high-risk patients with the 3-year freedom from biochemical fail-
ure being 100% for the high-dose SABR group (37.5 Gy in five
fractions) and 72% for the low dose group [35 or 36.25 Gy in five
fractions, p= 0.03 (29)].This dose response was not maintained
in the pooled analysis from the multi-institutional SABR consor-
tium (30). In the study by Bolzicco et al., patients across all risk
categories were treated with 35 Gy in five daily fractions using
robotic non-coplanar technique. The 3-year bRFS was 94.4%,
with four biochemical failures in intermediate and high-risk group
patients (31).
Based on the toxicity profile of pHART3, a phase 2 prospec-
tive dose escalated SABR trial of 40 Gy in five fractions over
29 days for low and intermediate-risk prostate cancer patients was
started in 2010. Using the linear quadratic equation with an α/β
of 1.3 (6), a dose of 40 Gy in five fractions would be equivalent
to 113 Gy delivered in 2 Gy fractions. For normal tissues such
as rectum, assuming an α/β of 4, this would be equivalent to
80 Gy in 2 Gy fractions. This estimate may be conservative, given
studies reporting the α/β of rectal tissue to be even higher (7).
This dose is similar to our HDR+ EBRT program (24) (EQD2
111 Gy, HDR 15 Gy with EBRT 37.5 Gy in 15 fractions), which
demonstrated encouraging biochemical and toxicity outcomes.
A similar benefit was also shown in the study by Taira et al.,
where EBRT at a dose of 45 Gy in 25 fractions was combined with
LDR boost (I-125 (144 Gy) or Pd-103(108 Gy).The 12-year bRFS
was 98.7, 95.9, and 90.4% for low, intermediate, and high-risk
patients.
Treatment in phart 6 was delivered using SSIMRT technique
using daily image guidance with gold seed fiducials and a 5-mm
CTV-PTV margin. Thirty patients have been treated with a median
follow-up of 24 months and no biochemical failures, grade 3+
acute or late toxicities have been observed (32). When phart 6 was
compared with phart 3, there was no difference in grade+ GU or
GI toxicities but there were significant differences in QOL favoring
the pHART3 protocol (smaller margin, lower dose), especially for
the bowel bother domain (32).This is likely due to a dose and also
volume effect, given the 5-mm margin. As a result of this, in our
next generation SABR studies (phart 10 and phart 11), we have
reduced the CTV-PTV margin to 3 mm and also reduced the PTV
dose to match the phart 3 PTV dose (33.25 Gy). This reduction in
margin was also facilitated by the change in treatment technique
from SSIMRT (33) to VMAT (34).
pHART7: LOW AND INTERMEDIATE RISK
Given that prostate cancer is a slow-growing malignancy, differ-
ences of 1–2 weeks in the overall treatment time between extreme
hypofractionated radiotherapy schedules are unlikely to impact
bRFS since treatment is completed within a short time (less than
30 days) (35, 36) but this has not been properly tested.
In contrast, small differences in treatment times can have
impact on toxicity. In a study from Stanford delivering 36.25 Gy
in five fractions, patients were initially treated in five consecutive
days and the second cohort was treated on alternate days (20).
Comparing the late GU and GI toxicities between two groups,
the rate of grade 1–2 GU toxicity was 56 vs. 17%(p= 0.007) and
grade 1–2 GI toxicity was 44 vs. 5%(p= 0.001) both favoring the
every other day schedule. The difference in grade 3 GU toxicity
was not statistically significant, likely due to small numbers (6 vs.
2%, p= 0.48) (37).
In this Canadian, multicentre, randomized phase II study
(pHART7), 152 patients with low- and intermediate-risk prostate
cancer were randomized to receive 40 Gy in five fractions over
29 days (one 8 Gy fraction per week) or over 11 days (one 8 Gy
fraction every other day, excluding weekends). Entire prostate plus
an additional 0.5 cm margin comprised PTV and treatment was
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delivered using theVMAT technique. The primary endpoint (acute
QOL) results will be presented in early 2015.
pHART10: LOW AND INTERMEDIATE RISK
As the next logical extension of SABR protocols, Odette cancer
centre has developed a two-fraction SABR treatment protocol
(pHART10) prescribing a dose of 26 Gy in two fractions to the
prostate (CTV) and a PTV dose of 22 Gy in two fractions. Using
an α/β ratio of 1.4 (6), this would be equal to EQD2 of 110 Gy
to CTV (equivalent to our 40 Gy in five fraction SABR and our
HDR/EBRT protocol) and 80 Gy to PTV (equivalent to 33.25 Gy
in five fractions, the PTV dose in pHART3). The rectal and bladder
EQD2 would be 55–62 Gy (using α/β ratios of 3–4).
The CTV–PTV margin is 3 mm. Due to the reduction in treat-
ment time with VMAT over SSIMRT, the prostatic intra-fraction
motion has reduced, which in turn facilitated the change in
CTV-PTV margin from 5 mm (33) to 3 mm (34).
3D datasets and anterior rectal doses were acquired via optically
stimulated luminescence (OSL) detectors held by a purpose-built
intrarectal acrylic stem and stand (like an endorectal balloon).
This protocol has been active since January 2014 and completed
accrual within 8 months. Acute toxicity, prostate immobilization,
and data about adequacy of PTV margins will be presented in
early 2015.
pHART8: HIGH RISK
The current standard of treatment for high risk locally advanced
non-metastatic prostate cancer patients is combined T and ADT
(38–40). Several EBRT dose escalation studies including standard
and hypo-fractionation schedules have shown improvement in the
5-year bRFS in this cohort (2, 13, 15). LDR brachytherapy boost
has shown excellent long-term results (41) and randomized data
from the ASCENDE-RT study (dose escalated RT vs. LDR boost
for high-intermediate or high-risk patients) is anticipated in 2015.
SABR was investigated by other investigators in the high-risk
setting. Doses ranging from 35 to 37.5 Gy in five fractions using
robotic non-coplanar technique (29, 31, 42, 43) and 43.84–45.2 Gy
in eight fractions using gantry-based technique (44) have been
described. The 6-year bRFS was 69% in the Katz et al. (42) cohort
and the 3 year bRFS was 77.1% in the Oliai et al. group (29).
The role of dose escalated SABR beyond 37.5 Gy in high-risk
patients is yet to be explored completely. This led to development
of pHART8 protocol in 2011, in which the entire prostate was
contoured as CTV2; the inferior 1.5 cm of seminal vesicles (entire
SVs if T3b) were contoured as the CTV1, with a 5-mm margin for
PTV1 and PTV2. An optimized radiotherapy plan was developed
to treat the PTV2 to 40 Gy in five fractions (EQD2 of 103 Gy with
anα/β of 1.8) (7); PTV1 received 30 Gy in five fractions (equivalent
to 62 Gy in 2 Gy fractions). ADT was stopped after 36 months (45).
Thirty patients have been treated and no acute grade 3 toxicities
were observed.
pHART11: HIGH RISK
The role of ENI in high-risk prostate cancer remains controver-
sial (46–48). In most of the EORTC and RTOG trials, the pelvis
received a dose of 45–50 Gy to cover occult metastatic disease in
the lymph nodes.
As most of the studies were done in pre-IGRT era (and therefore
substantial volumes of pelvic nodal tissue may have been missed
using standard bony landmarks), there is a requirement to evaluate
the role of pelvic RT in the era of technical advances (49). RTOG
0924 study evaluating the role of ENI is ongoing.
Katz et al. have treated around 100 high-risk pts with either
SABR alone (35–36.25 Gy in five fractions) or 63–66 Gy in 28
fractions (18–21 Gy in three fractions – SABR prostate boost),
simultaneously delivering 45 Gy in 25 fractions to the pelvic lymph
node targets. At a median follow-up of 5 years, there was no dif-
ference in bRFS or GU toxicity (44). Lack of benefit with the
addition of EBRT could be due to the small sample size in each
cohort (SABR-52pts, EBRT+ SABR-45pts). Grade 2 GI toxicity
was higher in patients who received pelvic EBRT (13.3% vs. 0,
p= 0.0019). A 3D conformal technique was used to treat pelvic
lymph nodes and this might explain the increase in bowel toxicity
for this cohort. The reduction in toxicity with the change in radi-
ation technique from 3D conformal to IMRT was demonstrated
nicely in out phart 2 protocol (12). The experience with using
40 Gy to the prostate while treating the pelvic lymph nodes in five
fractions is limited.
This led to the inception of pHART11 (SATURN) protocol. In
this study, VMAT was used to treat CTV1 to 25 Gy and CTV2
to 40 Gy in five (weekly) fractions concomitantly, using daily
CBCT pre- and post-treatment. PTV1 (23.75 Gy in five fractions)
included a 6-mm margin around the CTV nodes (50) and semi-
nal vesicles while the CTV2 (prostate) with a 3-mm margin was
contoured as PTV2 (33.25 Gy in five actions-PTV dose in phart 3
study) (34). This protocol completed accrual in September 2014
and the acute toxicity results will be presented early 2015.
DISCUSSION
Given the success of SABR in treating lung cancer (51, 52), it is
now being evaluated to treat other sites including spine, liver, and
prostate.
US-based SABR consortium reported outcomes in 1100 local-
ized prostate cancer patients treated with robotic non-coplanar
SABR to a median dose of 36.25 Gy (range 35–40 Gy) in four to
five fractions. At a median follow up of 36 months, the 5-year
bRFS was 95, 84, and 81% for low, intermediate, and high-risk
patients, respectively (53). As many patients experience benign
bounce post-treatment, bRFS appears to be better for patients
with longer follow-up: 99% for low risk, 93% for intermediate
risk (22).
Prostate SABR trials have shown late grade 3 GI and urinary
toxicities to be 1–3% (30). A QOL analysis for the 864 patients
in the multi-institutional cohort showed a transient decline in the
urinary and bowel domains within the first 3 months after SABR,
which returned to baseline within 6 months. Sexual QOL decline
was noticed within the first 9 months, irrespective of the use of
ADT or age (53).
Given that the majority of local relapses occur at the site of
primary tumor following radiotherapy for prostate cancer (54,
55), and to minimize the QOL decrements associated with whole
gland boost, the next step would be dose painting with focal
boost to the dominant nodule. A planning study by Udrescu et al.,
demonstrated a significant improvement in the bladder and rectal
Frontiers in Oncology | Radiation Oncology November 2014 | Volume 4 | Article 313 | 4
Musunuru et al. Sunnybrook SABR prostate
dosimetry in the MRI based focal boost plan when compared to the
whole gland boost (56). In the study by Aluwini et al., 50 low- and
intermediate-risk prostate cancer patients were treated with SABR
to a total dose of 38 Gy delivered in four daily fractions and an inte-
grated boost of up to 11 Gy per fraction was applied to the dom-
inant lesion visible on MRI. At a median follow up of 23 months;
acute Grade 3 GI and GU toxicity was 2 and 8%, and late Grade 3
GI and GU toxicity was 0 and 6%, respectively (57). This remains
experimental and is being tested in multiple phase II studies. In
these studies prostate and the visible dominant lesion will receive
a dose anywhere between 36.25–45 Gy and 38–50 Gy, respectively
(clinical trials.gov- NCT01409473, NCT01856855, NCT02145494,
NCT01976962).
Other possibilities of focal dose escalation in the investigational
setting include the utility of (11) C-choline PET for dose painting
the dominant nodule (58).
CONCLUSION
Stereotactic ablative body radiotherapy appears to be promising
in low- and intermediate-risk prostate cancer and remains experi-
mental in high-risk cohort with uncertainties about radiotherapy
dose, ENI, and the duration of ADT. Studies showing that SABR
can be safely delivered using a gantry-based platform (22) make it
feasible to utilize this technique in public health care models as it
is also economically valuable (59).
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